SIC
BPMC

SJS Investment Consulting’s Blueprint Medicines BPMC Stock Holding History

SJS Investment Consulting’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$0 Buy
+1
New +$72 ﹤0.01% 761

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SJS Investment Consulting's BPMC Position: Q1 2022 in Review

SJS Investment Consulting opened a new position in Blueprint Medicines (BPMC) in Q1 2022: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #761 among its holdings.

248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • SJS Investment Consulting held 1 share of Blueprint Medicines worth $0 as of Q1 2022.
  • Blueprint Medicines was a new SJS Investment Consulting position in Q1 2022.
  • Blueprint Medicines made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2022, its #761 holding.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on SJS Investment Consulting's 13F filing for Q1 2022, filed 5 May 2022.